MT1G and nonpapillary renal cell carcinoma: Sorafenib resistance experiments demonstrated that MT1G overexpression significantly reduced the sensitivity of ccRCC cells to sorafenib, while MT1G knockdown enhanced sensitivity (Supplementary Fig. 3i-j).